St. Louis Startup Canopy Biosciences Acquired By Bruker Corp.
The St. Louis startup Canopy Biosciences was founded by BioGenerator, the investment arm of innovation hub BioSTL, in 2016. Canopy Biosciences is an emerging life science company. They have successfully identified cutting-edge technologies from some of the world’s most respected academic institutions and rapidly brought them to market as innovative products and services.
Canopy offers gene editing, gene expression and bioprocessing products through their multi-omic platform of services combining the latest, most cutting-edge technologies to study the Genome, Transcriptome, Proteome and Microbiome.
Canopy has built a network of distributors spanning the entire globe. With a team built around sales and marketing veterans in the life science industry, they have been able to communicate the technical information of their products along with how they will help research. Through their products, Canopy has taken even the most complex technologies and made them simple by providing easy-to-use kits.
Recently, Canopy Biosciences was acquired by publicly traded Bruker Corp. Bruker Corp. is a scientific instrument maker headquartered near Boston. Canopy’s operations will continue through the BioSTL building in the Cortex district of St. Louis as a wholly owned subsidiary of Bruker.
“We are excited to add the multi-omics and high-content cytometry expertise of Canopy, and its novel ChipCytometry platform to Bruker,” said Dr. Mark Munch, the Bruker NANO group president, in a statement. “Canopy has a unique set of products that enable single cell, tissue and suspended cell-based discovery and validation in immunology and targeted proteomics, as well as a suite of complementary multi-omics services.”